Cargando…

A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders

Objectives: In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety lead-in study), the long-term safety and tolerability of vortioxetine (5–20 mg/day) were investigated in children and adolescents with a DSM-IV-TR™ diagnosis of depressive or anxiety d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Findling, Robert L., Robb, Adelaide S., DelBello, Melissa P., Huss, Michael, McNamara, Nora K., Sarkis, Elias H., Scheffer, Russell E., Poulsen, Lis H., Chen, Grace, Lemming, Ole M., Auby, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771527/ https://www.ncbi.nlm.nih.gov/pubmed/29035574 http://dx.doi.org/10.1089/cap.2017.0047

Ejemplares similares

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
por: Baldwin, David S, et al.
Publicado: (2016)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014)

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Jacobsen, Paula L., et al.
Publicado: (2015)

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Alam, Mohammed Y., et al.
Publicado: (2014)

Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium
por: Chen, Grace, et al.
Publicado: (2016)

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
por: Shah, Anish, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

RisksAssociated with Vortioxetine in the Established Therapeutic Indication
por: Verma, Akansha, et al.
Publicado: (2021)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Potential Effect of Vortioxetine on Restless Leg Syndrome
por: Alıcı, Yasemin Hoşgören, et al.
Publicado: (2023)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD)
por: Ng, Chong Guan, et al.
Publicado: (2023)

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
por: Chen, Grace, et al.
Publicado: (2013)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data
por: Post, Robert M., et al.
Publicado: (2020)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Vortioxetine overdose in a suicidal attempt: A case report
por: Mazza, Mario Gennaro, et al.
Publicado: (2018)

Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
por: Waller, Jessica A., et al.
Publicado: (2017)

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
por: Mills, Natalie T, et al.
Publicado: (2020)

Cognitive effects of vortioxetine in older adults: a systematic review
por: Bishop, Makenna M., et al.
Publicado: (2021)

Vortioxetine Induced Hypomania: A Case Presentation and Review of the Literature
por: Tunc, Ece Buyuksandalyaci, et al.
Publicado: (2022)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2021)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
por: Mattingly, G., et al.
Publicado: (2021)

Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
por: Budrow, Carla, et al.
Publicado: (2023)

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled, Randomized Trials
por: Wietecha, Linda A., et al.
Publicado: (2016)

Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram
por: Chakroborty, Shreaya, et al.
Publicado: (2017)

PS110. Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine
por: Christensen, AK, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c9hao46a1b9vnr71k092jhdjs2